-
HIV-positive and HIV-negative activists have partnered hand-in-hand for nearly thirty years to advocate for both care and treatment for people with HIV and prevention services for those not living with the virus. I hope when it comes to PrEP we can overcome fear, suspicion and rancor and ensure that this partnership stays strong.
4 hours ago | Poz blogs
-
A drug that has been shown to prevent HIV infection in a significant number of cases must be combined with behavioral approaches if the US health care establishment is to succeed in reducing the spread of the virus, according to the American Psychological Association.
15 May 2012 | Eurekalert Medicine & Health
-
A panel of advisers to the Food and Drug Administration took a historic step last week when they recommended that the agency for the first time approve a drug that healthy people can take once a day to prevent HIV infection.
15 May 2012 | New York Times
-
The issue of PrEP leaves the HIV/AIDS community divided.
14 May 2012 | The Body
-
As the US Food and Drug Administration moves closer to approving a drug that would reduce the likelihood of contracting HIV, critics and some health campaigners have raised fears that the pre-emptive treatment might actually lead to higher infection rates.
14 May 2012 | Financial Times
-
The first drug shown to prevent HIV infection won the endorsement of an FDA advisory panel Thursday, clearing the way for a landmark approval in the 30-year fight against the virus that causes AIDS.
11 May 2012 | Los Angeles Times
-
AVAC hails the recommendation by an FDA Advisory Committee that emtricitabine/tenofovir disoproxil fumarate (TDF/FTC or Truvada) be approved for use as pre-exposure prophylaxis (PrEP) among sexually active adult men and women. Citing the urgent need for new HIV prevention options to stem HIV infections, AVAC urges the FDA to issue an approval for all men and women at risk, and is calling on public health agencies, governments, advocates and funders to take action to ensure access to TDF/FTC as PrEP.
11 May 2012 | AVAC press release
-
Gilead Sciences Inc. (GILD) (GILD)’s pill Truvada was safe and effective when used to protect uninfected people from getting HIV, an advisory panel to the U.S. regulators said in a report; instead, they indicated that their main concerns are when and how it should be used.
The FDA is meeting on 10th May to decide whether to license the drug for Pre-Expposure Prophylaxis (PrEP). It is not obliged to follow the advice of its advisory panel.
08 May 2012 | Bloomberg
-
In part I of this two-part blog series, Jim Pickett talks about his experiences at the recently concluded Microbicides 2012 conference in Sydney and the buzz among advocates and trial designers today.
02 May 2012 | Mapping Pathways
-
In public comments submitted this week, a group of 14 leading HIV/AIDS and health organizations stated their support for Food and Drug Administration (FDA) approval of emtricitabine/ tenofovir disoproxil fumarate (TDF/FTC or Truvada®) as pre-exposure prophylaxis (PrEP) to prevent HIV infection in adult men and women.
02 May 2012 | MarketWatch (press release)
Talking points: a checklist for you and your doctorTalking points is designed to help you talk to your doctor about HIV
treatment.
Preventing HIVAn essential resource providing evidence-based information on preventing HIV infection. 
HIV, stigma and discrimination is now available in print!17 May 2012This week, boxes of the brand-new edition of our booklet...
Come and see us at the BHIVA conference!18 April 2012This morning, I boarded a train at Euston with one...
Community action on harm reduction (CAHR)16 April 2012We’ve been working on the design and
development of a new...